MedTrace Logo

Effect of Postbiotic Product on Colonic Barriers in IBS

NCT05475314 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-07-26

No results posted yet for this study

Summary

Impaired intestinal permeability and microbial dysbiosis are important pathophysiological mechanisms underlying irritable bowel syndrome (IBS). ReFerm®, also called Profermin®, is a postbiotic product of oat gruel fermented with Lactobacillus plantarum 299v. In this experimental study, we investigated whether ReFerm® has a beneficial effect on the intestinal epithelial barrier function in patients with IBS.

Conditions

  • IBS - Irritable Bowel Syndrome

Interventions

DIETARY_SUPPLEMENT

ReFerm(R)

Enemas of approx 250 mL twice daily

Sponsors & Collaborators

  • University Hospital, Linkoeping

    collaborator OTHER

  • Linkoeping University

    collaborator OTHER_GOV

  • Nordisk Rebalance A/S

    lead INDUSTRY

Principal Investigators

  • Susanna Walter, MD · University Hospital, Linköping, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-04-30
Completion
2022-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05475314 on ClinicalTrials.gov